Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / idr-25-response.docx
idr-25-response.docx
Parties
HARKNESS LLP
Penterra Pharmaceuticals Corp
Associates LLP
Whitmore Valuation Group LLC
Glenrock Services Inc
Dates
February 15, 2023
June 8, 2022
January 18, 2023
January 23, 2023
August 1, 2022
June 20, 2022
January 1, 2013
January 1, 2012
Amounts
€47.2
$814,600,000
$36,657,000 2018
$762,300,000
$34,303,500 2019
$691,800,000
$31,131,000 2020
$624,100,000
$28,084,500
Obligations
482-1(c), which provides that the arm's-length result of a controlled transaction must be determined under the method that, given the facts and circumstances, provides the most reliable measure of an arm's-length result
The licensed intellectual property must relate to the pharmaceutical or biotechnology sector, encompassing small-molecule drugs, biologics, and related pharmaceutical technologies
The licensed territory must be comparable to the non-Americas territory defined in the Legacy IP License, or must encompass global rights, ex-U
The license agreement must have been executed within a reasonable time frame relative to the years at issue, specifically during the period from 2012 through 2020
The transaction must have been entered into between unrelated parties dealing at arm's length